Eli Lilly’s retatrutide added to its regulatory path after two additional Phase 3 obesity readouts, with the company signaling it will seek FDA approval early next year. In the Triumph-2 and Triumph-3 studies, the highest doses produced peak weight loss of 20.8% and 22.6% at 80 weeks. Lilly also reported that the trials included participants with serious type 2 diabetes and cardiovascular complications, but the company did not show a clear cardiovascular risk reduction. Analysts and observers will now focus on how Lilly frames overall benefit beyond weight loss as the BLA filing approaches. The results extend the “triple-G” profile that already positioned retatrutide as one of the most closely watched late-stage obesity candidates, with competition centered on glucagon-like peptide-1 and dual agonist classes. Near-term, the clinical questions shift from magnitude of weight loss to durability, safety signal management, and whether any secondary endpoints meaningfully support long-term outcomes claims in regulatory submissions.